The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
Malignancies, Stomach Cancer, Non-small Cell Lung Cancer
About this trial
This is an interventional treatment trial for Malignancies focused on measuring RGD PET-CT, Apatinib
Eligibility Criteria
Inclusion Criteria:
- Clinical diagnosis of malignancies
- Scheduled for second- or third-line apatinib therapy
- Karnofsky performance status (KPS) ≥70
- Measurable primary tumors according to Response Evaluation Criteria in Solid Tumors (RECIST)
Exclusion Criteria:
- Active infection, myocardial infarction within 6 months, symptoms of heart disease, including unstable angina, congestive heart failure or uncontrolled arrhythmias, immunosuppressive therapy
- The claustrophobic patients and patients with implanted metal objects
- The pregnancy
- Inability to complete the required examinations
Sites / Locations
Arms of the Study
Arm 1
Experimental
Apatinib & RGD PET/CT
All of the patients will receive apatinib at oral dose of 250 mg twice daily (500 mg/day) at least 30 days.One treatment cycle is defined as 4 weeks.18F-ALF-NOTA-PRGD2 PET/CT scan will be performed berore and after one cycle of therapy. Treatment interruptions or dose reductions to 250 mg/day will be allowed for the management of adverse events. The maximum allowable period of treatment interruption is 1 week during each treatment cycle, and the dose should be re-escalated to 500 mg/day after adverse events mitigation. Treatment will not stop until disease progression, intolerable toxicity, or patients' request for withdrawal from the study.